NASDAQ$ENTA
Enanta Pharmaceuticals Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Reported financial results for the first quarter of fiscal year 2021.
Enanta Pharmaceuticals reported a decrease in total revenue due to lower HCV product sales by AbbVie, resulting in a net loss for the quarter, while advancing its pipeline programs in HBV and RSV.
- Royalty revenue for the quarter was $31.7 million.
- Cash and marketable securities totaled $404.7 million at the end of the quarter.
- Initiated RSVTx, a Phase 2b study of EDP-938 in adult hematopoietic cell transplant recipients with acute Respiratory Syncytial Virus (RSV) infection.
- Broadened Hepatitis B Virus (HBV) Program with EDP-721, a New Oral HBV RNA Destabilizer, as a Potential Component of a Functional HBV Cure Regimen; Plan to Initiate Phase 1 Study Mid-2021.
Headline financials
Revenue & EPS history
Enanta Pharmaceuticals · Revenue · Quarterly
$31.7M
Revenue by segment
Enanta Pharmaceuticals · $31.7M total across 1 segment · Q1 2021
- Royalty Revenue$31.7M-39.7%100.0%
Forward guidance
Enanta expects to progress through numerous milestones across its entire pipeline in the upcoming year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2021
-1.3%
Avg return
Earnings day
-1.2%
Avg return
5 days after
-1.0%
Avg return
30 days after
41%
24 / 58 earnings
Positive
+14.8%
Q4 2021
Best reaction
-29.2%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -6.1% | -13.4% | -26.0% | |
| Q1 2026 | +2.2% | +0.1% | -3.0% | |
| Q4 2025 | -3.5% | -0.7% | +13.3% | |
| Q2 2025 | -5.6% | +3.6% | +33.5% | |
| Q1 2025 | +14.1% | +45.7% | +39.4% | |
| Q4 2024 | -8.4% | -7.9% | -34.7% | |
| Q3 2024 | -6.5% | -9.5% | -12.7% | |
| Q2 2024 | -13.6% | -16.6% | -18.3% | |
| Q1 2024 | -1.4% | -1.7% | +22.8% | |
| Q4 2023 | +9.2% | +8.9% | -6.7% | |
| Q3 2023 | -6.6% | -19.8% | -38.8% | |
| Q2 2023 | -29.2% | -29.7% | -27.0% | |
| Q1 2023 | -0.5% | +0.2% | -12.1% | |
| Q4 2022 | -2.9% | -11.2% | +0.3% | |
| Q3 2022 | -3.8% | -4.2% | -10.4% | |
| Q2 2022 | -1.9% | -13.2% | -24.4% | |
| Q1 2022 | +2.8% | +1.8% | +3.9% | |
| Q4 2021 | +14.8% | +22.0% | +2.7% | |
| Q3 2021 | +5.6% | +6.3% | +35.8% | |
| Q2 2021 | -6.9% | -5.6% | -8.5% | |
| Q1 2021 | +3.1% | -3.3% | -3.9% | |
| Q4 2020 | -1.6% | -1.5% | -2.9% | |
| Q3 2020 | -2.1% | +0.2% | +4.4% | |
| Q2 2020 | -0.6% | +1.8% | -0.5% | |
| Q1 2020 | -0.1% | -5.4% | -2.3% | |
| Q4 2019 | -1.8% | +1.1% | +3.4% | |
| Q3 2019 | +6.0% | +7.4% | +0.7% | |
| Q2 2019 | -0.0% | -3.2% | +0.5% | |
| Q1 2019 | +11.6% | +11.2% | +22.9% | |
| Q4 2018 | +1.5% | +0.2% | -11.1% | |
| Q3 2018 | -6.4% | -6.3% | -11.4% | |
| Q2 2018 | -4.5% | -3.6% | +7.7% | |
| Q1 2018 | -19.0% | -16.7% | -7.5% | |
| Q4 2017 | -5.9% | -1.4% | +18.0% | |
| Q3 2017 | +2.2% | +2.0% | +11.6% | |
| Q2 2017 | +9.3% | +8.0% | -3.3% | |
| Q1 2017 | -6.5% | -7.5% | -8.9% | |
| Q4 2016 | +7.4% | +9.0% | +10.0% | |
| Q3 2016 | +2.3% | +6.4% | +4.3% | |
| Q2 2016 | -1.8% | — | — | |
| Q1 2016 | +1.8% | — | — | |
| Q4 2015 | -2.0% | — | — | |
| Q3 2015 | -13.8% | — | — | |
| Q2 2015 | -0.1% | — | — | |
| Q1 2015 | -4.2% | — | — | |
| Q4 2014 | +4.3% | — | — | |
| Q3 2014 | +4.6% | — | — | |
| Q2 2014 | +5.2% | — | — | |
| Q1 2014 | -3.6% | — | — | |
| Q1 2013 | -3.6% | — | — | |
| Q4 2011 | -22.6% | — | — | |
| Q1 2012 | -22.6% | — | — | |
| Q4 2013 | +8.5% | — | — | |
| Q3 2013 | +7.4% | — | — | |
| Q3 2012 | +7.4% | — | — | |
| Q2 2012 | +5.5% | — | — | |
| Q4 2012 | +5.5% | — | — | |
| Q2 2013 | +0.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro